IL6 and neoplasm: However, the same study found that the combination of IL-6 inhibitors and CD40 agonists do successfully reduce GBM resistance to immune-checkpoint therapy, but that the triple therapy (CD40 antibody, IL-6 antibody, and ICIs) is required for tumor regression and increased median survival in mice (21 days to 37 days) (122).